Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Fang Xie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2667-281X; OpenAlex author ID A5047243131. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers

Papers 8

  1. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00330-023-09679-w↗
  2. Retraction Note: The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine. Co-author DOI 10.1038/s41598-023-48298-9↗
  3. Downregulation of long noncoding RNA SNHG14 suppresses cell proliferation and invasion by regulating EZH2 in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.3233/cbm-190908↗
  4. The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine. Co-author DOI 10.1038/s41598-018-26496-0↗
  5. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. Co-author PMID 28123853↗
  6. HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Co-author DOI 10.1158/0008-5472.can-15-0671↗
  7. Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein. Co-author DOI 10.18632/oncotarget.11780↗
  8. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Co-author DOI 10.1093/carcin/bgr105↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiansheng Lin · 4 shared papers, 2016–2023 · strength 0.47
  2. Qiang Huang · 3 shared papers, 2016–2023 · strength 0.35
  3. Zhen Liu · 2 shared papers, 2018–2023 · strength 0.28
  4. Yanyan Kong · 1 shared paper, 2023 · strength 0.15
  5. Yihui Guan · 1 shared paper, 2023 · strength 0.15
  6. Di Yang · 1 shared paper, 2023 · strength 0.15
  7. Cheng Wang · 1 shared paper, 2020 · strength 0.12
  8. Chao Wang · 1 shared paper, 2020 · strength 0.12
  9. Luming Liu · 1 shared paper, 2017 · strength 0.07
  10. Chao Qu · 1 shared paper, 2017 · strength 0.07
  11. Peng Wang · 1 shared paper, 2017 · strength 0.07
  12. Qing Wang · 1 shared paper, 2017 · strength 0.07
  13. Zhiqiang Meng · 1 shared paper, 2017 · strength 0.07
  14. Lianyu Chen · 1 shared paper, 2017 · strength 0.07
  15. Zhenkun Lou · 1 shared paper, 2016 · strength 0.05
  16. Liewei Wang · 1 shared paper, 2016 · strength 0.05
  17. Wenhui Lou · 1 shared paper, 2016 · strength 0.05
  18. Yuan Fang · 1 shared paper, 2016 · strength 0.05
  19. Tongzheng Liu · 1 shared paper, 2016 · strength 0.05
  20. Min Deng · 1 shared paper, 2016 · strength 0.05
  21. Xiangui Hu · 1 shared paper, 2011 · strength 0.03
  22. Jun Hao · 1 shared paper, 2011 · strength 0.03
  23. Shuyu Zhang · 1 shared paper, 2011 · strength 0.03
  24. Cong Liu · 1 shared paper, 2011 · strength 0.03
  25. Chenghao Shao · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.